These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 19339179)

  • 1. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform.
    Rano TA; Sieber-McMaster E; Pelton PD; Yang M; Demarest KT; Kuo GH
    Bioorg Med Chem Lett; 2009 May; 19(9):2456-60. PubMed ID: 19339179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
    Barter PJ; Kastelein JJ
    J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors.
    Eary CT; Jones ZS; Groneberg RD; Burgess LE; Mareska DA; Drew MD; Blake JF; Laird ER; Balachari D; O'Sullivan M; Allen A; Marsh V
    Bioorg Med Chem Lett; 2007 May; 17(9):2608-13. PubMed ID: 17331716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CETP inhibition in cardiovascular risk management: a critical appraisal.
    Dullaart RP; Dallinga-Thie GM; Wolffenbuttel BH; van Tol A
    Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential for CETP inhibition to reduce cardiovascular disease risk.
    Ansell B; Hobbs FD
    Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of (2R,alphaS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor.
    Kuo GH; Rano T; Pelton P; Demarest KT; Gibbs AC; Murray WV; Damiano BP; Connelly MA
    J Med Chem; 2009 Mar; 52(6):1768-72. PubMed ID: 19236017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dalcetrapib: a review of Phase II data.
    Robinson JG
    Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H
    Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
    Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
    Zhao L; Jin W; Rader D; Packard C; Feuerstein G
    Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors.
    Escribano A; Mateo AI; Martin de la Nava EM; Mayhugh DR; Cockerham SL; Beyer TP; Schmidt RJ; Cao G; Zhang Y; Jones TM; Borel AG; Sweetana SA; Cannady EA; Mantlo NB
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3671-5. PubMed ID: 22543028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors.
    Lu Z; Chen YH; Napolitano JB; Taylor G; Ali A; Hammond ML; Deng Q; Tan E; Tong X; Xu SS; Latham MJ; Peterson LB; Anderson MS; Eveland SS; Guo Q; Hyland SA; Milot DP; Chen Y; Sparrow CP; Wright SD; Sinclair PJ
    Bioorg Med Chem Lett; 2012 Jan; 22(1):199-203. PubMed ID: 22142541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is high HDL cholesterol always good?
    Olsson AG
    Ann Med; 2009; 41(1):11-8. PubMed ID: 19085339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.
    Wang A; Prouty CP; Pelton PD; Yong M; Demarest KT; Murray WV; Kuo GH
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1432-5. PubMed ID: 20089400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.